HIV-Associated Neurocognitive Disorders (HAND)

HIV-Associated Neurocognitive Disorders (HAND)

Introduction

Hiv Associated Neurocognitive Disorders (Hand) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

HIV-Associated Neurocognitive Disorders (HAND) encompass a spectrum of neurocognitive impairments caused by human immunodeficiency virus (HIV) infection of the central nervous system (CNS). Despite the success of combination antiretroviral therapy (cART) in suppressing systemic viral loads and extending life expectancy, HAND remains a major complication affecting an estimated 30–60% of people living with HIV (PLWH) worldwide . The brain serves as a viral sanctuary where HIV can persist and replicate even when peripheral viral suppression is achieved, leading to chronic [neuroinflammation](/mechanisms/neuroinflammation), synaptic injury, and progressive neurocognitive decline . [@gut]

HAND was first recognized in the 1980s as AIDS dementia complex (ADC), a devastating condition causing severe cognitive, motor, and behavioral dysfunction. With the advent of cART in the mid-1990s, the incidence of the most severe form (HIV-associated dementia) has declined dramatically, but milder forms of neurocognitive impairment have become more prevalent, representing an emerging challenge in chronic HIV management . [@metaanalysis]

Classification (Frascati Criteria)

HIV-Associated Neurocognitive Disorders (HAND)

Introduction

Hiv Associated Neurocognitive Disorders (Hand) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

HIV-Associated Neurocognitive Disorders (HAND) encompass a spectrum of neurocognitive impairments caused by human immunodeficiency virus (HIV) infection of the central nervous system (CNS). Despite the success of combination antiretroviral therapy (cART) in suppressing systemic viral loads and extending life expectancy, HAND remains a major complication affecting an estimated 30–60% of people living with HIV (PLWH) worldwide . The brain serves as a viral sanctuary where HIV can persist and replicate even when peripheral viral suppression is achieved, leading to chronic [neuroinflammation](/mechanisms/neuroinflammation), synaptic injury, and progressive neurocognitive decline . [@gut]

HAND was first recognized in the 1980s as AIDS dementia complex (ADC), a devastating condition causing severe cognitive, motor, and behavioral dysfunction. With the advent of cART in the mid-1990s, the incidence of the most severe form (HIV-associated dementia) has declined dramatically, but milder forms of neurocognitive impairment have become more prevalent, representing an emerging challenge in chronic HIV management . [@metaanalysis]

Classification (Frascati Criteria)

The 2007 Frascati criteria established a standardized classification system for HAND, defining three categories of increasing severity : [@exploring]

Asymptomatic Neurocognitive Impairment (ANI)

• Performance ≥1 standard deviation (SD) below the normative mean in ≥2 cognitive domains on standardized neuropsychological testing
• No interference with everyday functioning
• Prevalence: approximately 26% of PLWH
• Represents the most common HAND subtype in the cART era

HIV-Associated Mild Neurocognitive Disorder (MND)

• Performance ≥1 SD below normative data in ≥2 cognitive domains
• Mild-to-moderate interference with daily functioning (work, home management, social activities)
• Prevalence: approximately 8.5% of PLWH

HIV-Associated Dementia (HAD)

• Performance ≥2 SD below normative data in ≥2 cognitive domains
• Marked interference with daily functioning
• Prevalence: approximately 2.1% of PLWH in the cART era (down from 15–20% pre-cART)
• Historically the most feared neurological complication of AIDS

Pathogenesis

CNS Entry and Viral Reservoirs

HIV enters the CNS early during primary infection via a "Trojan horse" mechanism, crossing the [blood-brain-barrier](/entities/blood-brain-barrier) within infected monocytes and CD4+ T lymphocytes [@communityled]))](https://pmc.ncbi.nlm.nih.gov/articles/PMC4937456/). Once inside the CNS, the virus productively infects [microglia[/doi:10.1093/brain/awaa219">2</a>[/doi:10.1093/brain/awaa219">2</a>[/doi:10.1093/brain/awaa219">2</a>/doi:10.1093/brain/awaa219">2<)(https://pmc.ncbi.nlm.nih.gov/articles/PMC10615506/). [^6]
HIV enters the CNS early during primary infection via a "Trojan horse" mechanism, crossing the [blood-brain-barrier](/entities/blood-brain-barrier) within infected monocytes and CD4+ T lymphocytes . Once inside the CNS, the virus productively infects [microglia/](https://pmc.ncbi.nlm.nih.gov/articles/PMC10615506/). [^7]

Viral Protein Neurotoxicity

• HIV-1 Tat (transactivator of transcription): Secreted by infected cells, Tat directly impairs synaptic function, disrupts calcium homeostasis, promotes neuronal [apoptosis](/mechanisms/apoptosis), and potentiates [excitotoxicity](/mechanisms/excitotoxicity) through [nmda-receptor](/entities/nmda-receptor) receptor] receptor dysregulation [@communityled]))](https://pmc.ncbi.nlm.nih.gov/articles/PMC4937456/)
• gp120 (envelope glycoprotein): Triggers [oxidative-stress](/mechanisms/oxidative-stress) and [mitochondrial-dysfunction](/mechanisms/mitochondrial-dysfunction) in [neurons](/entities/neurons), and activates [microglia](/cell-types/microglia):69-81. [doi:10.1038/nri1527" title="^6]: Gonzalez-Scarano F, Martin-Garcia J. The neuropathogenesis of AIDS. Nat Rev Immunol. 2005;5(1):69-81. [doi:10.1038/nri1527">6</a>))](https://link.springer.com/article/10.1186/s12987-020-00204-5)
• Vpr (viral protein R): Induces cell cycle arrest and [apoptosis](/mechanisms/apoptosis) in [neurons](/entities/neurons) and glia [@communityled]))](https://pmc.ncbi.nlm.nih.gov/articles/PMC4937456/)

• HIV-1 Tat (transactivator of transcription): Secreted by infected cells, Tat directly impairs synaptic function, disrupts calcium homeostasis, promotes neuronal apoptosis, and potentiates [excitotoxicity](/mechanisms/excitotoxicity) through [nmda-receptor](/entities/nmda-receptor) receptor] receptor] receptor dysregulation
• gp120 (envelope glycoprotein): Triggers [oxidative-stress](/mechanisms/oxidative-stress) and [mitochondrial-dysfunction](/mechanisms/mitochondrial-dysfunction) in [neurons](/entities/neurons), and activates [microglia/](https://link.springer.com/article/10.1186/s12987-020-00204-5)
• Vpr (viral protein R): Induces cell cycle arrest and [apoptosis](/mechanisms/apoptosis) in [neurons](/entities/neurons) and glia

neuroinflammation

• Pro-inflammatory cytokines: TNF-α, IL-1β, IL-6, and interferon-γ
• Chemokines: CCL2/MCP-1, CXCL10, and fractalkine
• [oxidative-stress](/mechanisms/oxidative-stress) and nitrogen species
• Quinolinic acid (an [nmda-receptor](/entities/nmda-receptor) receptor] receptor] agonist and excitotoxin)
• Platelet-activating factor and arachidonic acid metabolites

Blood-Brain Barrier Disruption

HIV infection leads to increased permeability of the [blood-brain-barrier](/entities/blood-brain-barrier) through multiple mechanisms: viral proteins (Tat and gp120) directly disrupt tight junction proteins, inflammatory mediators degrade the basement membrane, and activated monocytes transmigrate across the endothelium. [blood-brain-barrier](/entities/blood-brain-barrier) breakdown allows entry of viral particles, infected cells, and neurotoxic plasma proteins into the brain parenchyma . [^11]

Synaptic Degeneration

HAND involves vulnerability of neural circuits caused by synaptic degeneration and abnormal dendritic pruning. Loss of synaptic density, particularly in the [hippocampus](/brain-regions/hippocampus) and [cortex](/brain-regions/cortex), correlates more closely with cognitive impairment than neuronal loss, paralleling mechanisms observed in [alzheimers](/diseases/alzheimers-disease) . [^12]

Clinical Features

Cognitive Domains Affected

HAND typically affects the following cognitive domains: [^13]

• Attention and working memory: Difficulty concentrating and processing information
• Executive function: Impaired planning, decision-making, and mental flexibility
• Processing speed: Slowed information processing
• Learning and memory: Difficulty encoding new information (retrieval typically better preserved than in [Alzheimer's Disease)
• Motor function: Psychomotor slowing, fine motor impairment, gait abnormalities
• Language: Generally preserved until advanced stages

Behavioral and Psychiatric Symptoms

• Apathy and motivational deficits
• Depression (highly prevalent, complicating diagnosis)
• Irritability and emotional lability
• Social withdrawal
• In HAD: personality changes, psychosis, and mania may occur

Diagnosis

Screening Tools

• International HIV Dementia Scale (IHDS): A brief bedside screening tool assessing timed finger tapping, timed alternating hand sequences, and recall. Pooled sensitivity for HAND detection is approximately 62%, with higher sensitivity for HAD (74.3%) [@effect]))](https://pmc.ncbi.nlm.nih.gov/articles/PMC8235728/)
• HIV Dementia Scale (HDS): Original screening tool with higher sensitivity for HAD than milder forms
• Montreal Cognitive Assessment (MoCA): Commonly used but not HIV-specific
• International HIV Dementia Scale (IHDS): A brief bedside screening tool assessing timed finger tapping, timed alternating hand sequences, and recall. Pooled sensitivity for HAND detection is approximately 62%, with higher sensitivity for HAD (74.3%)
• HIV Dementia Scale (HDS): Original screening tool with higher sensitivity for HAD than milder forms
• Montreal Cognitive Assessment (MoCA): Commonly used but not HIV-specific

Neuropsychological Assessment

Formal neuropsychological testing across multiple cognitive domains remains the gold standard for HAND diagnosis. A comprehensive battery should assess at least five cognitive areas, with demographically adjusted norms accounting for age, education, and cultural background . [^14]

Neuroimaging

• MRI: Cortical and subcortical atrophy, white matter hyperintensities, [basal-ganglia](/brain-regions/basal-ganglia) volume loss
• Diffusion tensor imaging (DTI): White matter microstructural changes preceding macroscopic damage
• Functional MRI: Altered network connectivity, particularly in frontostriatal circuits
• MR spectroscopy: Elevated choline and myoinositol (glial activation markers), decreased N-acetylaspartate (neuronal integrity marker)

Biomarkers

• CSF markers: [nfl-protein](/proteins/nfl-protein) ([neurofilament-light](/biomarkers/neurofilament-light-chain-nfl)), CSF HIV RNA, [glial-fibrillary-acidic-protein](/entities/glial-fibrillary-acidic-protein), and inflammatory cytokines
• Plasma markers: [neurofilament-light](/biomarkers/neurofilament-light-chain-nfl)) may serve as a non-invasive biomarker of CNS injury

Treatment

Antiretroviral Therapy

cART remains the cornerstone of HAND management. Selection of ART regimens with high CNS penetration-effectiveness (CPE) scores may improve neurological outcomes, though this remains debated . Key considerations include: [^15]

• Early ART initiation to limit viral seeding of the CNS
• Optimization of regimens for [blood-brain-barrier](/entities/blood-brain-barrier) penetration
• Management of persistent CSF viral escape

Adjunctive Pharmacological Approaches

• [memantine](/therapeutics/memantine): [nmda-receptor](/entities/nmda-receptor) receptor] receptor antagonist to mitigate excitotoxicity
• Minocycline: Anti-inflammatory and neuroprotective properties
• Lithium: [gsk3-beta](/mechanisms/gsk3-beta) inhibition and neuroprotection
• Statins: Anti-inflammatory effects and [blood-brain-barrier](/entities/blood-brain-barrier) stabilization
• Intranasal insulin: Targeting insulin signaling pathways in the brain

• [memantine](/therapeutics/memantine): [nmda-receptor](/entities/nmda-receptor) receptor] receptor] receptor antagonist to mitigate excitotoxicity
• Minocycline: Anti-inflammatory and neuroprotective properties
• Lithium: [gsk3-beta](/mechanisms/gsk3-beta) inhibition and neuroprotection
• Statins: Anti-inflammatory effects and [blood-brain-barrier](/entities/blood-brain-barrier) stabilization
• Intranasal insulin: Targeting insulin signaling pathways in the brain

Non-Pharmacological Interventions

• Cognitive rehabilitation: Structured training programs targeting impaired domains
• Physical exercise: Regular aerobic exercise associated with improved cognitive outcomes
• Psychosocial support: Addressing depression, substance use, and social isolation
• Management of comorbidities: Cardiovascular disease, metabolic syndrome, hepatitis C co-infection

Relationship to Neurodegenerative Diseases

HAND shares several pathogenic mechanisms with classic neurodegenerative diseases, particularly [alzheimers](/diseases/alzheimers-disease): [^17]

• Amyloid pathology: PLWH show accelerated [amyloid-beta](/proteins/amyloid-beta) deposition, and HIV-1 Tat inhibits [neprilysin](/proteins/neprilysin), a major [amyloid-beta](/proteins/amyloid-beta)-degrading enzyme
• [tau-protein](/proteins/tau) pathology]: Hyperphosphorylated tau] is found in HIV-positive brains, particularly in those with cognitive impairment
• [neuroinflammation](/mechanisms/neuroinflammation): Chronic microglial activation is a shared feature
• [oxidative-stress](/mechanisms/oxidative-stress): Mitochondrial dysfunction and [oxidative-stress](/mechanisms/oxidative-stress) accumulation are central to both HAND and AD
• [autophagy](/mechanisms/autophagy-lysosome-neurodegeneration)mechanisms/autophagy)-lysosomal dysfunction]: HIV proteins impair [autophagy](/mechanisms/autophagy-lysosome-neurodegeneration)mechanisms/autophagy), leading to accumulation of toxic protein aggregates
• Accelerated aging: PLWH show features of premature brain aging, including early-onset cognitive decline and reduced brain volume

Background

The study of Hiv Associated Neurocognitive Disorders (Hand) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development. [^19]

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions. [^20]

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/) - Biomedical literature
• [Alzheimer's Disease Neuroimaging Initiative](https://adni.loni.usc.edu/) - Research data
• [Allen Brain Atlas](https://brain-map.org/) - Brain gene expression data

See Also

• [microglia[/[Memantine[/[Memantine[/[Memantine[/[Memantine[/[Memantine[/[Memantine](/Memantine)(/therapeutics/memantine)

Recent Research (2024-2026)

This section highlights recent publications relevant to this disease.

• [Community-Led Total Sanitation implementation in Malawi: process evaluation of a sanitation and hygiene intervention.](https://pubmed.ncbi.nlm.nih.gov/41764035/) (2026 Dec 31) - Global public health
• [Gut microbiome remodeling induced by microplastic exposure in humans.](https://pubmed.ncbi.nlm.nih.gov/41552974/) (2026 Dec 31) - Gut microbes
• [Meta-analysis of handgrip strength in subjects with high-normal or mildly increased uric acid compared to low-normal levels reported as quartiles.](https://pubmed.ncbi.nlm.nih.gov/41486688/) (2026 Dec 31) - Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology
• [Exploring the mechanism of polymorphonuclear neutrophils against sepsis based on immune model.](https://pubmed.ncbi.nlm.nih.gov/41814716/) (2026 Dec) - Annals of medicine
• [Effect of changes in the arm physical parameters on the minimum torque-change trajectories of human reaching movements.](https://pubmed.ncbi.nlm.nih.gov/41798052/) (2026 Dec) - Cognitive neurodynamics

Pathway Diagram

References